These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30619772)

  • 1. Efficacy and Affecting Factors of
    Wang C; Diao H; Ren P; Wang X; Wang Y; Zhao W
    Front Oncol; 2018; 8():640. PubMed ID: 30619772
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy.
    Zubair Hussain S; Zaman MU; Malik S; Ram N; Asghar A; Rabbani U; Aftab N; Islam N
    J Thyroid Res; 2014; 2014():610273. PubMed ID: 24987542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
    Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
    Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between Variation of Pre-ablation Stimulated Thyroglobulin and Distant Metastasis in Patients with Differentiated Thyroid Cancer.
    Zhao T; Liang J; Li TJ; Li CX; Hui C; Yang K; Li F; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Jun; 37(3):315-9. PubMed ID: 26149144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
    Claimon A; Pusuwan P; Khiewvan B
    J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
    Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
    Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
    Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
    Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
    Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
    Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation.
    Lu L; Li Q; Ge Z; Lu Y; Lin C; Lv J; Huang J; Mu X; Fu W
    Front Endocrinol (Lausanne); 2024; 15():1361683. PubMed ID: 38872967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient thyroid remnant ablation using repeated low 131-iodine activities (740 MBq/20 mCix2) in patients with low-risk differentiated thyroid cancer.
    Clerc J; Bienvenu-Perrard M; de Malleray CP; Dagousset F; Delbot T; Dreyfuss M; Groussin L; Marlowe RJ; Leger FA; Chevalier A
    J Clin Endocrinol Metab; 2012 Mar; 97(3):871-80. PubMed ID: 22238400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.